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Objective: To review and summarize biomarker data published from April 2014 to May 2015 to provide
insight to the ongoing work in the ﬁeld of osteoarthritis (OA). Furthermore, to summarize the BIPED
criteria and set it in context of the medical needs of 2015.
Methods: PubMed was used as searching machine: Time period 2014/04/01e2015/05/01, MeSH term
[Biomarker] AND [Osteoarthritis], Language; English, Full text available. Reviewswere excluded. Only papers
describing protein based biomarkers measured in human body ﬂuids from OA patients were included.
Results: Biomarkers of joint tissue turnover, cytokines, chemokines and peptide arrays were measured in
different cohorts and studies. Amongst those were previously tested biomarkers such as osteocalcin,
Carboxy-terminal cross-linked fragment of type II collagen (CTX-II) and cartilage oligomeric matrix
protein (COMP). A majority of the biomarker were classiﬁed as I, B or B biomarkers according to the
BIPED criteria.
Work is continuing on testing biomarkers in OA. There is still a huge, unmet medical need to identify,
test, validate and qualify novel and well-known biomarkers. A pre-requisite for this is better charac-
terization and classiﬁcation of biomarkers to their needs, which may not be reached before higher un-
derstanding of OA phenotypes has been gained. In addition, we provide some references to some recent
guidelines from Food and Drug Administration (FDA) and European Medicines Agency (EMA) on quali-
ﬁcation and usage of biomarkers for drug development and personalized medicine, which may provide
value to the ﬁeld.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
There is still a need for biomarkers in osteoarthritis (OA) for
diagnosis, prognosis and monitoring of disease activity in clinical
practice, as well as biomarkers for patient selection and study: A.C. Bay-Jensen, Rheuma-
rlev, Denmark. Tel: 45-44-54-
ay-Jensen).
r Ltd and Osteoarthritis Research Sdesign optimization in clinical interventional trials1. To date limited
biomarkers have been approved by the regulatory authorities for
theses uses in OA; however multiple biomarkers have been
developed and tested over the last decades. Also, in 2014, new
biomarkers were investigated, alongside evaluation of well-known
biomarkers.
The US Food and Drug Administration (FDA) and European
Medicines Agency (EMA), have recently published different
guidelines recommending a higher level of integration of bio-
markers in the development and testing of new drugs to advance
decision-making on dosing, time and treatment effect, trial design,ociety International. This is an open access article under the CC BY-NC-ND license
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references at the end of the article) It is believed that by imple-
menting biomarkers for screening of drug candidates in early
clinical development (e.g., in vitro and/or pre-clinically), potential
safety issues can be addressed in advance, and hence increase the
drug development efﬁciency, and possibly reduce the overall cost of
running and OA clinical trial2. The primary objective of using bio-
markers in drug development is to identify a sub-population of
responsive subjects that will provide best evidence for rejecting the
null hypothesis of no treatment effect, and thereby demonstrate
the efﬁcacy and the safety of a drug candidate. Since biomarkers are
considered as objective measures of biological, pathological or
pharmacological events, the probability of false positives and false
negatives selection becomes reduced compared to patient
recruitment based on objective measures such as Visual analog
score (VAS) pain. Consequently, the power calculation for future
clinical trials will result in a smaller sample size.
Biomarkers can be used not only in the process of drug devel-
opment, but also in assessment of individual patient's response to
treatment. By evaluating the biomarker result, clinicians will be
able to conclude whether the treatment has the desired effect or
not. The BIPED classiﬁcation categorizes biomarkers according to
key parameters for evaluation and qualiﬁcation of the utility of
biomarkers. Those are: Burden of disease (B), Investigative (I),
Prognostic (P), Efﬁcacy of intervention (E) and Diagnostic (D)3.
In this review, we provide a systematic review of soluble
biochemical markers (biomarkers) recently tested in clinical
studies and cohorts. Furthermore, we highlight recent studies
applying biomarkers in OA. In conclusion, we provide interpreta-
tion on how to classify biomarkers according to the BIPED criteria
by differentiating each of the categories as of 2015.
Methods
The article consists of three parts. The ﬁrst part summarizes
peer reviewed papers on biomarkers published between April 1st
2014 and May 1st 2015. PubMed was used to search the time range,
in combination with the MeSH terms BIOMARKER AND OSTEO-
ARTHRITIS. From the initial search 115 articles were listed. Next, the
list was further processed by only including publications written in
English, reducing the list to 113; all were available as full text pa-
pers. Fourteen review articles were excluded from the list, leaving
99 original research articles for inclusion in the review process.
Each article was carefully studied and only articles including
measurement of protein or peptide-based soluble biomarkers in
serum, plasma, synovial ﬂuid (SF) and urine of either OA patients or
preclinical OA-associated models were included. Six articles
describing the usage of biomarkers tested in animal models
(Table S1)92e96 and 41 describing the testing in clinical studies
(Table I) were reviewed and tabulated in this review article. Fifty
two articles were excluded because they were either: (1) not
assessed in OA associated models/samples, (2) not soluble protein-
derived biomarkers, or (3) not utilizing biomarkers in the study/
publication although.
The second part of the article investigates the total number of
publications publically available on each of the biomarkers
described in the ﬁrst part which reﬂects joint tissue turnover. The
number of publications was investigated by searching on PubMed,
using the biomarker name together with the MeSH term OSTEO-
ARTHRITIS. Review articles were excluded. The limitation of the
search was spelling mistakes and uncommon abbreviations, which
may have led to unidentiﬁed publications. The numbers given in
Table II are therefore an estimate, which should only be used as an
information pointing towards the number of investigations pub-
lished on individual biomarkers during the last decades.The third part is a perspective (narrative) view on the usage of
the biomarkers and how to use the BIPED classiﬁcation to under-
stand the utility of the biomarkers.
Biomarkers tested in clinical OA studies and cohorts
Different classes of biomarkers were tested in the 2014/2015
period targeting mainly two classes: (1) biomarkers of joint tissue
turnover and (2) biomarkers of (pro-) inﬂammatory status. Table I
summarizes the biomarkers tested in human OA samples. The
BIPED classiﬁcation in which the authors tested the hypothesis is
given in the table.
During the past year several inﬂammatory biomarkers have
been described, including cytokines, chemokines, or cell type
markers important for OA pathology4e8. Another group of the
newly identiﬁed biomarkers were biomarkers reﬂecting the turn-
over of the extracellular matrix (ECM) of the diseased cartilage9e11,
while the remaining biomarkers targeted auto-antibodies,
signaling molecules, or growth factors12e19. Many of these bio-
markers were investigated based on the knowledge of OA pathol-
ogy: Daghestani4 worked from the hypothesis that inﬂammatory
OA has a higher degree of activated macrophages, leading to a
shedding of the macrophage cell markers: CD163 and CD14. In their
study, they found these two markers indeed were increased and
correlated to the severity and progression of OA symptoms4.
The hypothesis of another study was based on fractalkine
(CX3CL1) playing a role in inﬂammation and chronic pain, and this
study showed that CX3CL1 levels in serum and SF were correlated
with WOMAC pain and WOMAC total scores5. Some biomarkers
were identiﬁed using high-throughput methods like afﬁnity pro-
teomics and mass spectrometry. Afﬁnity proteomics and antigen
microarrays were used to detect auto-antibodies in human OA
serum. Normally auto-antibodies are known from autoimmune
disease like rheumatoid arthritis, but this study found auto-
antibodies against potassium channels, carbohydrate sulfo-
transferase, and interleukin-6 (IL-6) in human OA serum14.
Mass spectrometry was used to investigate tryptic digested
cartilage slides from young, aging, and OA horses to identify ECM
proteins and ECM fragments related to OA cartilage and non-aging
cartilage. This study found disease-speciﬁc ﬁbromodulin and
biglycan peptides that were not linked to aging, and that addi-
tionally identiﬁed a number of ﬁbronectin fragments with
increased abundance in OA cartilage as tentative biomarkers9.
Selected reaction monitoring mass spectrometry, which enable
measurements of several proteins in one sample, was used to
identify clusterin and lubricin in human OA plasma as predictors of
OA progression, with a prediction level equal to age17.
In general the biomarkers identiﬁed were either identiﬁed as
diagnostic biomarkers or burden of disease markers in serum,
plasma, or SF. However, many of them were found in small sample
sizes, and it is therefore important to further investigate these
biomarkers in larger sample sizes. Additionally biomarkers
measured in human SF were only measured in OA SF, as it is an
invasive and unethical procedure to obtain SF from healthy control
individuals. Biomarkers measured in SF were only correlated to
serum or plasma levels and used to look at progression.
More established biomarkers that have previously been sug-
gested as biomarkers that may correlate with features of OA, were
tested in larger sample sizes and populations to further charac-
terize the potential use of these biomarkers. Arendt-Nielsen and
colleagues showed that the degradation fragment of CRP, CRPM,
correlated with the degree of sensitization in a group of symp-
tomatic OA patients (n ¼ 281)20, indicating a connection between
pain sensitization and chronic inﬂammation. Carboxy-terminal
cross-linked fragment of type II collagen (CTX-II) wasmeasured in a
Table I
Clinical biomarker overview. The biomarkers are listed in alphabetic order
Biomarker Sample type Results (short description) Ref ID BIPED classiﬁcation
Alpha-CTX Urine SKOA and RKOA (n ¼ 149). a-CTX was strongly correlated with
subchondral bone turnover, JSN and osteophyte progression.
37 Prognostic
ADAMTS-4 Serum Early OA (n ¼ 44), intermediate and late OA (n ¼ 26),
healthy control (n ¼ 30). ADAMTS-4 was signiﬁcantly
increased in patients with early OA compared to intermediate
and advanced OA groups as well as controls.
38 Burden of disease
ADAMTS-5 Serum Early OA (n ¼ 44), intermediate and late OA (n ¼ 26),
healthy control (n ¼ 30). ADAMTS-5 was signiﬁcantly higher
in intermediate and advanced OA compared to early OA and
controls.
38 Burden of disease
ARGS Serum, Urine, Plasma Healthy subjects (n ¼ 20), Non-surgical OA (n ¼ 20),
OA subjects undergoing TKR (n ¼ 20). Serum and urine
ARGS associated with OA. SF ARGS was positively correlated
with WOMAC stiffness but not total WOMAC score.
39 Burden of disease
AGRS Synovial ﬂuid Acute knee injury (n ¼ 98). No association with
osteochondral fracture in the knee.
22 Burden of disease
Autotaxin Plasma, Synovial ﬂuid Control (n ¼ 20), KOA (n ¼ 70). Plasma and SF autotaxin
were associated with severity of RKOA and positively
correlated with WOMAC scores.
40 Burden of disease
BDNF Plasma, Synovial ﬂuid Healthy subjects (n ¼ 19), RKOA (n ¼ 27), Increased
plasma levels in RKOA patients compared to controls and
positively correlated with WOMAC score. No correlation
found with knee OA severity.
19 Diagnostic
C1M Serum Non-clinical OA to clinical OA (n ¼ 281). C1M showed
no association with intensity or duration of pain.
20 Burden of disease
C2C Serum, Synovial ﬂuid Subjects 0 days-7 years after knee injury
(SF n ¼ 235, serum n ¼ 71), controls (n ¼ 8). Increased
levels of C2C in injured knees 1 day-7 years after injury
compared to controls. Shortly after injury 1e33 days,
C2C concentrations were correlated with CTX-II, ARGS,
osteocalcin, osteopontin and IL-8, but not structural joint
injury by MRI.
41 Investigative
C2C Synovial ﬂuid Traumatic OA (n ¼ 8). Average cartilage strain at maximal
ﬂexion of the knee in patients with meniscal tear was not
associated with C2C.
42 Investigative
C2M Serum Non-clinical OA to clinical OA (n ¼ 281) e C2M showed
no association with intensity or duration of pain.
20 Burden of disease
C2M Serum OA KL 0e4 (n ¼ 271). Positive association with increased
levels of C2M.
10 Burden of disease
C3M Serum Non-clinical OA to clinical OA (n ¼ 281). C3M showed
no association with intensity or duration of pain.
20 Burden of disease
C-Col10 Serum OA KL 0e4 (n ¼ 271). C-Col10 was elevated in patients
with KL ¼ 2 compared to KL ¼ 0, and was elevated in
patients with above normal hsCRP.
10 Burden of disease
CCL2 Serum, Synovial ﬂuid Control (n ¼ 138), OA (n ¼ 161). CCL2 in SF but not in
serum associated with symptomatic severity of OA.
43 Burden of disease
CCL3 Plasma Non-radiographic KOA (n ¼ 47), RKOA (n ¼ 50) Control
(n ¼ 75). CCL3 associated with severity of KOA.
8 Burden of disease
CCL4 Plasma Non-radiographic KOA (n ¼ 47), RKOA (n ¼ 50) Control
(n ¼ 75). CCL4 associated with RKOA severity.
8 Burden of disease
CD14 Synovial ﬂuid
Plasma
RKOA (n ¼ 184). SF CD14 was positively associated with
JSN and osteophytes. CD14 in both plasma and SF was
positively associated with self reported knee pain in a
subgroup. SF CD14 was positively associated with
osteophyte progression.
4 Burden of disease
Prognostic
CD163 Synovial ﬂuid, plasma RKOA (n ¼ 184). SF CD163 was positively associated
with osteophyte progression.
4 Prognostic
CGRP Serum, Synovial ﬂuid KOA (n ¼ 65), control (n ¼ 21). CGRP was positively
correlated with KL score, total WOMAC as well as each
WOMAC subscale.
13 Burden of disease
Coll-2-1 Serum KOA (n ¼ 22) Curcumin treatment reduced Coll-2-1
serum levels.
44 Efﬁcacy of intervention
COLL-2-1NO2 Urine Overweight and obese middleaged women (n ¼ 254).
COLL-2-1NO2 at baseline is negatively associated with
incidence of knee OA.
45 Prognostic
Coll-2-1NO2 KOA (n ¼ 22). No association observed between
Coll-2-1NO2 and Curcumin treatment.
44 Efﬁcacy of intervention
COMP Serum RHOA (n ¼ 638). Symptoms of hand OA and higher
AUSCAN scores were associated with higher levels
of COMP. No association was found with radiographic
hand OA.
21 Burden of disease
COMP Synovial ﬂuid Traumatic OA (n ¼ 8). Average cartilage strain at
maximal ﬂexion of the knee in patients with
meniscal tear was not associated with COMP levels.
42 Investigative
(continued on next page)
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Table I (continued )
Biomarker Sample type Results (short description) Ref ID BIPED classiﬁcation
COMP Synovial ﬂuid Acute knee injury (n ¼ 98). No association with
osteochondral fracture in the knee.
22 Burden of disease
COMP Serum
Synovial ﬂuid
KOA with joint effusion (n ¼ 34). No correlation
between COMP and radiographic or ultrasonographic
ﬁndings were observed.
23 Burden of disease
CRP Serum Non-clinical OA to clinical OA (n ¼ 281). CRP showed
no association with intensity or duration of pain.
20 Burden of disease
CRP Serum KOA (n ¼ 22) treated with Curcumin. No association
observed between CRP and Curcumin treatment.
44 Efﬁcacy of intervention
CRPM Serum Non-clinical OA to clinical OA (n ¼ 281). CRPM
correlated with degree of centralized sensitization.
20 Burden of disease
CTX-II Urine SKOA and RKOA (n ¼ 149). CTX-II was strongly
associated with cartilage/bone interface bone
turnover, JSN, ostephyte severity and OA
progression based on ostephyte score.
37 Burden of disease
Prognostic
CTX-II Urine KOA (n ¼ 22) treated with Curcumin.
No association observed between CTX-II and
Curcumin treatment.
44 Efﬁcacy of intervention
CTX-II Urine Population (n ¼ 1040). Correlation between
CTX-II and KL score in women above 60
with OA.
46 Burden of disease
CX3CL1 Serum
Synovial ﬂuid
OA (n ¼ 193), Healthy controls (n ¼ 182).
CX3C1 levels in serum and SF were positively
associated with self reported pain and
disability measured by WOMAC score.
5 Burden of disease
FAC Synovial ﬂuid OA (n ¼ 17), non-OA (n ¼ 17) Negative
correlation with ROA at hip, but positively
with microdamage surgery in non-OA patients.
11 Burden of disease
FGF21 Serum, Synovial ﬂuid OA (n ¼ 186), control (n ¼ 108) Positive
correlation between increased levels of
FGF21 and OA and Ahlb€ack grade
(radiographic bone loss).
15 Burden of disease
Fib3-1 Serum KOA (n ¼ 22) treated with Curcumin.
No association observed between Fib3-1
and Curcumin treatment.
44 Efﬁcacy of intervention
Fib3-2 Serum KOA (n ¼ 22) treated with Curcumin No
association observed between Fib3-2 and
Curcumin treatment.
44 Efﬁcacy of intervention
Fib3-2 Serum In the PROOF study (n ¼ 242), baseline
Fibulin 3 epitopes (Fib3-1, Fib3-2 and Fib3-3)
concentrations are highly associated to the
incidence of clinical knee OA among
middle-aged overweight and obese women.
45 Diagnostic
HIF-1a Serum, Synovial ﬂuid KOA (n ¼ 278), healthy control (n ¼ 203)
Association between higher levels of HIF-1a
and increased radiographic severity of KOA.
12 Burden of disease
hmwAPN Serum RHOA (n ¼ 227). hmwAPN showed no
association with progression of RHOA.
47 Prognostic
IL-1b Synovial ﬂuid Acute knee injury (n ¼ 98). No association
with osteochondral fracture in the knee.
22 Burden of disease
IL-6 Synovial ﬂuid Acute knee injury (n ¼ 98). No association
with osteochondral fracture in the knee.
22 Burden of disease
IL-6 Plasma Non-radiographic KOA (n ¼ 47), RKOA
(n ¼ 50) Control (n ¼ 75). Associated
with RKOA severity.
8 Burden of disease
IL-8 Synovial ﬂuid Acute knee injury (n ¼ 98). Osteochondral
fractures with disrupted cortical bone had
increased IL-8 compared to non-osteochondral
fractures
22 Burden of disease
IL-8 Plasma Non-radiographic KOA (n ¼ 47), RKOA (n ¼ 50)
Control (n ¼ 75). Associated with RKOA severity.
8 Burden of disease
IL-10 Serum EHOA þ Fenoﬁbrate (n ¼ 14). Fenoﬁbrate
treatment of EHOA was associated with a
reduction in IL-10 levels.
48 Efﬁcacy of intervention
ihh Synovial ﬂuid Normal (n ¼ 25), early OA (n ¼ 50), late OA
(n ¼ 47). Increased ihh concentration in SF in
early but not late stage OA compared to controls.
18 Burden of disease
Leptin Serum Elderly Boston Study population (n ¼ 653).
Increased levels of leptin is associated with
increased risk of OA, suggesting that part of the
BMI risk factor is mediated through increased
leptin concentrations.
49 Prognostic
Leptin Serum
Synovial ﬂuid
KOA with joint effusion (n ¼ 34). Serum leptin
correlated with HAQ and length of medial ostephytes.
23 Burden of disease
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Table I (continued )
Biomarker Sample type Results (short description) Ref ID BIPED classiﬁcation
MMP-1 Serum Early OA (n ¼ 44), intermediate and late OA (n ¼ 26),
healthy control (n ¼ 30). MMP-1 was signiﬁcantly
higher in intermediate and advanced OA compared to
early OA and controls.
38 Burden of disease
MMP-3 Serum Early OA (n ¼ 44), intermediate and late OA (n ¼ 26),
healthy control (n ¼ 30). MMP-3 was signiﬁcantly
higher in intermediate and advanced OA compared
to early OA and controls.
38 Burden of disease
MMP13 Serum
Synovial ﬂuid
KOA with joint effusion (n ¼ 34). No correlation
between MMP13 and radiographic or ultrasonographic
ﬁndings were observed.
23 Burden of disease
MPO KOA (n ¼ 22) treated with Curcumin. No association
observed between MPO and Curcumin treatment.
44 Efﬁcacy of intervention
Neuropeptide Y (NPY) Synovial ﬂuid KOA (n ¼ 100), healthy control (n ¼ 20). NPY was
correlated with increased pain on the Hideo
Watanabe pain score and Tomihisa Koshino pain score.
50 Burden of disease
NTX-I Urine Population (n ¼ 1040). No association was found
between NTX-I levels and the different KL scores.
46 Burden of disease
Osteocalcin Synovial ﬂuid Acute knee injury (n ¼ 98). No association with
osteochondral fracture in the knee.
22 Burden of disease
Osteopontin Synovial ﬂuid Acute knee injury (n ¼ 98). No association with
osteochondral fracture in the knee.
22 Burden of disease
Prostaglandin E2 Synovial ﬂuid Traumatic OA (n ¼ 8). Average cartilage strain
at maximal ﬂexion of the knee in patients with
meniscal tear was not associated with,
Prostaglandin E2.
42 Investigative
Resistin Serum
Synovial ﬂuid
KOA with joint effusion (n ¼ 34). SF resistin
correlated with effusion.
23 Burden of disease
Resistin Plasma Non-radiographic KOA (n ¼ 47), RKOA (n ¼ 50)
Control (n ¼ 75). Resistin associated with RKOA
severity.
8 Burden of disease
S100A8/A9 Serum OA (n ¼ 162) No correlation with clinical features
of OA. Negative correlation with sum score of
osteophytes. Small positive association with ESR.
51 Burden of disease
Sclerostin Plasma, Synovial ﬂuid KOA (n ¼ 95), healthy control (n ¼ 95). Inverse
correlation between plasma and SF levels of
Sclerostin and RKOA.
16 Burden of disease
sCreatinine Serum CHECK population (n ¼ 738). Change in serum
creatinine does not explain the increase
observed in uCTX-II at menopause in the
CHECK cohort.
52 Investigative
sGAG Synovial ﬂuid Traumatic OA (n ¼ 8). Average cartilage strain
at maximal ﬂexion of the knee in patients with
meniscal tear was not associated with sGAG.
42 Investigative
sGAG Synovial ﬂuid Acute knee injury (n ¼ 98). No association with
osteochondral fracture in the knee.
22 Burden of disease
sHA Serum RHOA (n ¼ 638) Symptoms of hand OA and
higher AUSCAN scores were associated with
higher levels of sHA. Hand radiographic OA
associated with sHA.
21 Burden of disease
SPARC Synovial ﬂuid Acute knee injury (n ¼ 98). Osteochondral
fractures with disrupted cortical bone had
increased SPARC compared to
non-osteochondral fractures.
22 Burden of disease
TNF-a Synovial ﬂuid Acute knee injury (n ¼ 98). Increased
TNF-a associated with osteochondral fracture
in the knee. Osteochondral fractures with
disrupted cortical bone additionally had
increased SPARC, IL-8, and TNF-a compared
to non-osteochondral fractures.
22 Burden of disease
totAPN Serum RHOA (n ¼ 227). Inversely associated with
progression of RHOA. hmwAPN showed no
association with progression of RHOA.
47 Prognostic
VEGF Serum
Synovial ﬂuid
KOA with joint effusion (n ¼ 34).
VEGF correlated with degree of KL score
in OA patients and length of medial
osteophytes.
23,53 Burden of disease
Proteomic and Multiplex
approaches
Multiplex Synovial ﬂuid Unicompartmental KOA (n ¼ 30),
Bicompartmental KOA (n ¼ 29) Increased
cytokine levels in bicompartmental OA
compared to unicompartmental.
54 Investigative
(continued on next page)
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Table I (continued )
Biomarker Sample type Results (short description) Ref ID BIPED classiﬁcation
Multiplex Plasma
Synovial ﬂuid
KOA (n ¼ 31), Healthy control (n ¼ 15). PECAM-1,HGF,
VEGF, angiopoietin-2,
follistatin, G-CSF, and IL-8 were increased in OA compared
to controls. Plasma angiopoietin differentiated advanced
OA from early. SF VEGF was positively correlated with
severity. Plasma follistatin was negatively correlated
with severity.
7 Burden of disease
Multiplex Serum Normal (n ¼ 100), OA (n ¼ 100), RA (n ¼ 100). Systems
biology approach to distinguish OA patients from
RA and controls.
55 Diagnostic
Mass spectrometry Synovial ﬂuid OA (n ¼ 80). OA can be divided into distinct metabolic
subgroups.
56 Investigative
Mass spectrometry Plasma
Synovial ﬂuid
OA (n ¼ 69) Modest correlation between metabolite
concentrations in synovial ﬂuid and plasma.
57 Investigative
Mass spectrometry Serum
Synovial ﬂuid
Late stage OA (n ¼ 13), Cohort (n ¼ 253). Peptides from
clusterin, lumican, lubricin were associated with
joint space narrowing. Peptides from clusterin and
lubricin were as predictive of OA progression as age.
17 Investigative
Mass Spectrometry Cartilage explants An iTRAQ-based quantitative proteomic analysis of
secretomes from healthy human articular cartilage
explants, comparing their protein proﬁle to those
from unwounded (early disease) and wounded
(advanced disease) zones of osteoarthritic tissue.
58
Antigen microarray
(NAPPA)
Serum OA (n ¼ 21), RA (n ¼ 20), control (n ¼ 21)
Auto-antibodies identiﬁed, distinguishing OA, RA
and control subjects. Proteomic approach to identify
a panel of auto-antibodies for diagnosis and
prognosis of OA.
14 Investigative
Protein microarray Synovial ﬂuid
Serum
Long-term TMJ OA (n ¼ 28), Early TMJ OA
(n ¼ 12, Healthy control (n ¼ 12). Protein microarray
of 50 biomarkers. Synovial ﬂuid levels ANG, GDF15,
TIMP-1, CXCL16, MMP-3 and MMP-7 correlated
with bone apposition in the tempomandibular joint.
Serum levels of ENA-78, MMP-3, PAI-1, VE-Cad-herin,
VEGF, GM-CSF, TGFb1, IFNg, TNFa, IL-1a, and
IL-6 correlated with bone resorption at this site.
59 Investigative
Afﬁnity chromatography Synovial ﬂuid Acute trauma (n ¼ 19), Knee pain (n ¼ 16),
OA (n ¼ 20), RA (n ¼ 20). Identiﬁcation of 12 novel
COMP fragments from RA, OA or trauma patients.
60 Investigative
IL-6, KC/GRO, IL-8, (MCP-1),
(MIP-3a), IL-1b, TNF
and Lþ-lactate
Serum
Synovial ﬂuid
Clinical OA (n ¼ 6), Healthy controls (n ¼ 6).
When comparing the cytokine proﬁle between
synovial ﬂuid and serum from OA patients only
MIP-3a correlated signiﬁcantly.
61 Investigative
Abbreviations: FCA, Freund's complete adjuvant; FMCP, Fragmented medial coronoid process; Ihh, Indian Hedgehog; IL-1b, Interleukin-1b; KC/GRO; Keratinocyte chemo-
attractant/human growth-regulated oncogene; MCP-1, monocyte chemoattractant protein 1; MIP-3a, macrophage inﬂammatory protein 3a; MMP, Matrix metalloproteinase;
MPO, Myeloperoxidase; TNF-a, Tumor necrosis factor-a, WT; Wild-type.
A.C. Bay-Jensen et al. / Osteoarthritis and Cartilage 24 (2016) 9e2014large Japanese cohort of 1040 subjects. Here they found that CTX-II
correlated with OA severity in the form of KL score in OA patients
above 60 years of age.
Another highly investigated marker is cartilage oligomeric ma-
trix protein (COMP), which has beenmeasured in a number of trials
within this last year, with varying outcomes; it was shown to
correlate with hand OA symptoms and increased AUSCAN scores,
but not radiographic hand OA in cross-sectional study of 663 OA
patients21. In another set of studies looking at traumatic KOA, no
association was found between traumatic KOA severity and con-
centrations of COMP22. Finally, Kim and colleagues looked at the
correlation between COMP and OA in patients with synovitis, and
found no association with effusion23.
Probably the best tested biomarkers in OA are those reﬂecting
joint tissue turnover such as urinary CTX-II or serum COMP, which
both are believed to measure cartilage degradation24. One of the
reasons why these may be of higher interest for OA is that these
often have shown higher sensitivity and analyte stability, whereas
cytokines is generally of more acute nature with short half-life25.
Table II lists the biomarkers from Table I that measured tissue
turnover and which have been tested in human OA studies orcohorts within the last 3 decades. Both CTX-II and COMP have been
tested in more than 50 different studies, and may be the best
validated OA biomarkers to date. However although they have been
thoroughly tested the different datasets provide differential and
somewhat contradictory results. This may be due to the type of OA
patients tested, the design of the studies in respect to the hy-
pothesis tested, and the statistical analyze conducted. This can
make it rather difﬁcult to qualify the biomarkers according to
speciﬁc BIPED categories; however from a general view point these
biomarkers can be classiﬁed as burden of disease, diagnostic and
prognostic biomarkers.
When studying the list it stands out that most biomarkers
measure cartilage degradation or bone resorption. What is lacking
on the list are tests of cartilage formation/repair and synovial
inﬂammation, which are also believed to play an important role in
the pathogenesis of OA and are therefore imperative for a future
diagnostic toolbox for OA. Examples of formation/repair bio-
markers which have been developed and tested in human OA
studies are CS84626 and PIIANP27,28. For these to be validated more
clinical anabolic interventional studies with prospective biomarker
strategies are needed.
Table II
Number of publications the biomarkers identiﬁed in Table I, which reﬂect joint tissue turnover. *The number of publications on the individual biomarkers is an estimate
provided by pivotal search PubMed
Biomarker Description References (Max. 5
recent Publications)
Number of
publications*
Alpha CTX-I Cathepsin K degraded newly formed type I collagen 37 1
ARGS (different biomarker assays) Aggrecanase mediated degradation of aggrecan 22,39,62e64 22
C1M MMP-mediated degradation of type I collagen 20,65 2
C2C MMP-mediated degradation of type II collagen 66e70 24
C2M MMP-mediated degradation of type II collagen 10,20,65,71,72 5
C3M MMP-mediated degradation of type III collagen 20,65 2
COMP (several different biomarker assays) Cartilage oligomeric matrix protein turnover/degradation 60,71,73e75 >50
C-Col10 Release of type X collagen from cartilage 10 1
Coll-2-1 Protease-mediated degradation of type II collagen 44,76e79 5
Coll-2-1-NO2 Protease-mediated degradation of nitrosylated type II collagen 44,76e79 5
CTX-II Protease-mediated degradation of type II collagen 52,80e83 >50
Fib3-1 Protease-mediated degradation of Fibulin 3 44,84 2
Fib3-2 Protease-mediated degradation of Fibulin 3 44,84 2
NTX-I Cathepsin K degraded type I collagen 46,68,74,85,86 26
Osteocalcin (several different biomarkers) Bone formation 87e91 >50
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The BIPED classiﬁcation categorizes biomarkers according to key
parameters for evaluation and qualiﬁcation of the utility of bio-
markers. Those are: Burden of disease (B), Investigative (I), Prog-
nostic (P), Efﬁcacy of intervention (E) and Diagnostic (D)3. D-
biomarkers are those that will enable identiﬁcation of those pa-
tients with OA in the general population or speciﬁc phenotype of
OA patients (e.g., metabolic vs trauma), whereas B-biomarkers are
those which will aid in describing the disease burden or disease
severity at a given point in time (e.g., metabolic status, degree of
cartilage degradation). The B-biomarker is a snapshot of current
status of the disease. Present diagnostic and burden of disease
markers are radiographic images, as well as sign and symptoms
recorded by the physician and/or patient.
With respect to prognosis or prediction, FDA clearly distin-
guishes between these P markers. A prognostic biomarker is a
baseline characteristic that categorizes patients by degree of risk for
disease occurrence or progression of a speciﬁc aspect of a disease. A
prognostic biomarker informs about the natural history of the dis-
order in that particular patient in the absence of a therapeutic
intervention. It can be used as an enrichment strategy to select pa-
tients likely to have clinical events of interest or to progress rapidly.
A predictive biomarker is a baseline characteristic that catego-
rizes patients by their likelihood of response to a particular treat-
ment relative to no treatment. A predictive biomarker can be used as
an enrichment strategy to identify a subpopulation likely to respond
to a treatment intervention in a particular way. It may predict a
favorable response or an unfavorable response (i.e., adverse event).”
As such, The “P” (prognostic) biomarker is a marker which predicts
future outcomes, such as the risk (odds) for structural progression,
or other outcomes or events (e.g., joint inﬂammation, bone marrow
lesion, and joint failure). An example would be that a P biomarker
would identify those in most need of aggressive treatment, which
then may be eligible for special care or intervention.
An example of a Prognostic biomarker can be found in theﬁeld of
rheumatoid arthritis (RA), where the biomarker C1M was prog-
nostic of structural progression29, while a combination of bio-
markers were predictive of response to tocilizumab, an anti-
interleukin 6 receptor treatment29,30. A very important point for a
clear differentiation between a prognostic and predictive biomarker
is the needed level of qualiﬁcation of the individual biomarkers.
It is current BIPED description the predictive biomarker is an
integrated part of the E category. An “E” biomarker is marker for
measuring whether the drug is efﬁcacious and can be used in PhaseII dose-ﬁnding studies and, optimally, even prior to Phase II, for
faster evaluation of potential efﬁcacy. An example would be that an
early change in a biomarker will predict whether a drug will be
efﬁcacious; that is meeting its clinical endpoint. This is in contrast
to the predictive biomarker that will predict who will respond to a
given treatment at baseline. In OA, it would be desirable to have
available such biomarkers due to the long and vastly populated
clinical trials, as it would allow for earlier decision-making.
The predictive E biomarker can used to determine which pa-
tients are specially eligible for a given treatment, such as herceptin
is approved for the treatment of early-stage breast cancer that is
Human Epidermal growth factor Receptor 2-positive (HER2þ) and
has spread into the lymph nodes, or is HER2þ and has not spread
into the lymph nodes. If it has not spread into the lymph nodes, the
cancer needs to be estrogen receptor/progesterone receptor (ER/
PR)-negative or have one high risk feature. This way, the diagnostic
tool is linked to subsequent use of a treatment, in case of a positive
test. Hence, a predictive E biomarker wouldmost optimally be used
to determine which kind of treatment strategy a patient would
beneﬁt from, for example an anti-inﬂammatory drug (e.g., IL-1 anti-
IL1), an anti-resorptive drug31 (e.g., Zoledronate), or a cartilage
anabolic drug (e.g., FGF18)32.
It is important to note that FDA (and EMA) uses a different
nomenclature when deﬁning prediction and prognosis. According
to the FDA, the main separating factor is that a prognostic
biomarker provides you with an odds for progression, whereas a
predictive biomarker would be used to decide the exact treatment
regimen for individual patients, and would therefore have a sig-
niﬁcant impact on the patient's life. A predictive biomarker will
often become a companion diagnostic33. Please ﬁnd references to
important guidelines and documents at the end of the article.
In 2011, Kraus et al. modiﬁed the BIPED characterization by
adding a “S” for safety34. The purpose of the “S” biomarker was
ideally to monitor the health status of the joint tissue or general
cytotoxic status in response to treatment. One could imagine that a
relative ratio between an “E” and “S” biomarker could provide a
risk/beneﬁt ratio for a drug in a trial.
Finally, an “I” biomarker is a marker of which not sufﬁcient in-
formation is available yet to allow its inclusion in one of the other
categories. As no biomarkers have been qualiﬁed as biomarkers for
OA, this category covers the majority of biomarkers tested in OA.
It is important to test and validate a biomarker to a hypothesis
that covers just one of the classiﬁcations or test the classiﬁcation
individually. Although we in this paper and other in other papers
try to categorize the biomarkers according to the BIPED there is still
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most cohorts are tested retrospectively and no prospectively for
exactly validating a BIPED hypothesis. Also predictiveness toward
treatment efﬁcacy still needs to be tested, as there are only trials for
DMOARDs and even fewer (if any) testing biomarkers as outcome
measure. A good biomarker would only has to be validated for one
of the classiﬁcations other than “I” to qualify for the clinical usage.
Ongoing initiatives for validating and qualifying biomarkers
The issues in understanding OA patho-physiology and subse-
quent translational application of in vitro diagnostics of such un-
derstanding in drug development are large and complex,
Independent efforts have led to slow and insufﬁcient clinical
progress, as outlined above. Also the use of drug development tools
(DDT) is of particular interest, and biomarkers for e.g., progression
would be an advantage for patient selection in interventional trials.
Some of these challenges can be best addressed and the obstacles
be overcome by Public-Private-Partnerships (PPP) of engaged,
knowledgeable, and complimentary industrial, academic, patient
and governmental experts who can provide innovative and viable
solutions. Considering the scale of the problem and societal impact,
there remains a major unmet need as current treatments are pre-
dominantly restricted to symptomatic relief or costly and invasive
surgical intervention.
Multiple reasons have been identiﬁed as underlying causes of
past clinical failures:
 Limited understanding of OA pathogenesis. Emerging data
suggest OA is a heterogeneous disease with a variety of patho-
physiologic drivers, some of which are amenable to pharmaco-
logic intervention, and some of which are expected to be less so.
 Variable disease course. The majority of an unselected OA
population do not progress radiographically or clinically in a
given 2 year window; companies have not had the tools or
knowledge base to prospectively identify patients at risk of
progression who stand to beneﬁt the most from effective
therapies.
 Absence of personalized medicine mindset. Clinical develop-
ment plans have frequently used a ‘one size ﬁts all’ approach
rather thanmatchingmechanism of action to speciﬁc OA patient
subpopulations and using speciﬁc DDTs.
 Reliance on relatively insensitive endpoints. X-ray-based joint
space narrowing (the current standard endpoint to demonstrate
disease modiﬁcation) is insensitive, tends to be slowly evolving
and does not allow visualization of the tissue most associated
with the disease (cartilage).
 Lack of a qualiﬁcation strategy for the applied biomarkers and
DDTs in a clinical setting and for diagnosis.
In PPP consortia, these points are addressed in close collabora-
tion of different academic and industry partners. The FNIH/OARSI
initiative on OA biomarkers and imaging35 has just presented ﬁrst
comprehensive data on imaging and biochemical markers out of
the analysis (http://oarsi.org/sites/default/ﬁles/docs/2015/fnih_
2015_pre_congress_workshop_ﬁnal.pdf) and also reference in-
tervals for healthy subjects for the selected biomarkers36. A phase 2
of the initiative will further substantiate the ﬁndings and charac-
terize and validate biomarkers in different clinical cohorts. In
Europe the Innovative Medicine Initiative (IMI) has started to bring
further knowledge in the ﬁeld. In both initiatives several topics will
be addressed:
 Consolidated existing complementary OA data sets (public and
private) Deﬁnition and characterization of OA patient subsets, also using
bioinformatics
 Identiﬁcation of novel biomarkers for OA
 Biochemical marker assay platform validation and development
 Validation of biochemical markers and next generation imaging
technologies in a cohort of OA patients
 User-friendly interface where data can be publically accessed
and analyzed (e.g., OAI)
 Workwith regulators to ﬁnalize guidance and initiate regulatory
biomarker qualiﬁcation process
Lastly the D-BOARD consortium, an EU funded PPP initiative, is
working on identiﬁcation and validation of novel biomarkers and
pushing those forward toward qualiﬁcation, by applying the BIPED
categories for hypothesis testing (http://www.d-board.eu/dboard/
index.aspx).Conclusion
Work is continuing on testing biomarkers in OA and will need to
continue in the future, as present data do not reach and answer the
medical need in the ﬁeld. However much of validation and quali-
ﬁcation work is halted by the lack designated biomarker studies
and successful drug trials. Although interesting biomarkers have
been tested in 2014/2015, little clinical validation or qualiﬁcation
studies have been presented. Thus there is still a huge, unmet
medical need to identify, test, validate and qualify novel and well-
known biomarkers. A pre-requite for this is better characterization
and classiﬁcation of biomarkers to their needs, which may not be
reached before understanding of OA phenotypes has been much
improved. However this needs to be substantiated and supported
in a broader context including a reﬂection on the guidelines pro-
vided by the regulatory authorities, which extent outside of this
review. The running and upcoming PPP initiatives are expected to
select and push the best biomarkers forward towards qualiﬁcation.Documents of interest from the regulators
Following links provide some of the guidelines on qualiﬁcation
and approval routes published by the regulators, which may be of
great value for biomarker development for use drug development
and personalized medicine and health care.
 Presentation given by Dr. Shashi Amur (OTS, CDER, FDA) at the
M-CERSI symposium, C-Path (August 2015) providing encour-
agement and considerations for biomarker development and
qualiﬁcation. The talk was titled “FDA's efforts to encourage
biomarker development and qualiﬁcation”: http://c-path.org/
wp-content/uploads/2015/08/EvConsid-Symposium-20150821-
I-01-SAmur-FINAL.pdf
 Guidance for qualiﬁcation of drug development tools (DDT such
as biomarkers): http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM230597.pdf
 Report titled “Report on the use of omic technologies in the
development of personalized medicines (March 2013): http://
ec.europa.eu/health/ﬁles/committee/70meeting/pharm616.
pdf”. The report highlights the potentials and issues in research
and development of personalized medicine
 List of letters which include high-level summary of the novel
methodology, context of use, available data, and on-going and
future investigations: http://www.ema.europa.eu/ema/index.
jsp?curl¼pages/regulation/document_listing/document_
listing_000319.jsp&mid¼WC0b01ac0580022bb0
A.C. Bay-Jensen et al. / Osteoarthritis and Cartilage 24 (2016) 9e20 17 Guidance for industry on how to technically validated bio-
markers (May 2001). http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM070107.pdf
 A document titled: “Paving the way for personalized medicine:
FDA's role in a new Era of medical product development”.
Descripting the rational for personalized medicine and
providing examples of the biomarkers in use (October 2013):
http://www.fda.gov/downloads/scienceresearch/specialtopics/
personalizedmedicine/ucm372421.pdf)Contribution
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